Drug Trial Radar · NCT06261814
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
266
Planned (sponsor's estimate)
Start
Aug 7, 2024
Primary completion
Jul 1, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- john eisenbreyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Feb 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering Lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.
Conditions
- Liver Neoplasms
Interventions
Sulfur Hexafluoride Lipid MicrospheresDrug
Given IV
Contrast-Enhanced UltrasoundProcedure
Undergo CEUS
Transarterial ChemoembolizationProcedure
Undergo TACE
Medical Chart ReviewOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- RecurrenceTime frame: Up to 6 months
- SensitivityTime frame: Up to 6 months
- SpecificityTime frame: Up to 6 months
- Positive predictive valueTime frame: Up to 6 months
- Negative predictive valueTime frame: Up to 6 months
- False discovery rateTime frame: Up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.